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1. Introduction
Modern molecular and cytogenetic approaches have furthered progress in our understanding
of MM biology and have led to the development of targeted therapy that has improved
management of this incurable disease. Novel agents such as bortezomib, lenalidomide or
thalidomide, have increased median survival rates and improved prospects for MM patients
resistant to conventional therapy [1, 2]. Despite these therapeutic advances, MM remains a
very difficult disease to treat still accompanied by the threat of repeated relapses with a fatal
ending. These observations indicate that at least some of the MM cells are not targeted
efficiently by current drug therapies. The existence of such persistent populations, called
myeloma stem cells (MSC) or myeloma-initiating cells (MIC) has been suspected for more than
two decades. However, the cells of origin remain elusive [3-9]. Timeline of growing knowledge
about putative MSC is displayed in Figure 1. Discrepancies among myeloma stem cell concepts
have arisen in parallel with the high phenotypic heterogeneity of clonal PCs that might be
another factor contributing to the failure of therapies and identification of the population
responsible for relapse. Myeloma PCs strongly depends on the supportive role of the bone
marrow (BM) microenvironment (MEV) – it is a source of essential growth factors, supports
survival and dissemination of pathological PCs [10-14]. Furthermore, hypoxic conditions of
tumor microenvironments support tumor progression by inducing angiogenesis, maintaining
the malignant phenotype and stimulating osteoclastogenesis [15-18]. There is growing
evidence that signals from pathological microenvironments can (reversibly) alter the pheno‐
type of PCs. Such plasticity of PCs might result in obvious heterogeneity of MM and generate
inconsistencies among myeloma stem cell concepts.
© 2013 Šváchová et al.; licensee InTech. This is an open access article distributed under the terms of the
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Figure 1. Timeline of myeloma stem cell concepts
2. Myeloma stem cell concepts
A number of laboratories have tried to identify a biologically distinct population of so called
myeloma precursors or myeloma stem cells (MSC) which are responsible for the incurability of
MM (see Table 1). However, none of these concepts have been unambiguously proven until now.
With regards to the fact that abnormal PCs of MM show features of advanced differentiation and
mature morphology, the population responsible for the origin and sustainability of tumor mass
has been suspected in the minor population of clonotypic or clonogenic CD138- cells retaining
key stem cell properties, tumor-initiating potential, self-renewal and resistance to chemothera‐
py [6, 19-25]. However, it was demonstrated that even the dominant population of human CD138+
PCs contained clonogenic cells; these cells show plasticity potential that might be responsible for
dedifferentiation and acquiring of stem cell properties [8, 26-30].
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Characteristics of the cells Citation
Clo
no
typ
ic B
 ce
lls PB CD19, CD38, CD10, CD11b, CD34 (HPCA-1),
variable CD20, PCA-1, CD45RO, variable CD45, and
CD56
[19-23, 31-34]
PB CD34±, CD38+, CD184+, CD31±, CD50±, CD138-,
CD19-, CD20-
[35]
PB CD19+CD27+CD38- memory B-like cells [24]
Clo
no
typ
ic p
re-
sw
itc
h B
 ce
lls pre-switch somatically hypermutated clonotypic
cells (VDJ sequence still joined to Cμ gene)
PB and BM CD19, HLA class II or surface IgM
[36-38]
Clo
no
ge
nic
 CD
13
8- c
ell
s BM CD20+CD27+CD34-CD138- clonogenic myeloma
stem cells
[6, 39-41]
Sid
e p
op
ula
tio
n capacity to exclude dyes
sideways from the diagonal in FACS analysis plots
CD138- and CD138+
[42, 43]
Clo
no
ge
nic
 pl
asm
a c
ell
s BM CD38+CD45- PC (SCID-hu model)
BM clonogenic CD38+CD138-CD45- PC (SCID-rab
model)
[7, 26, 28]
BM CD38+CD138-CD45-CD19-CD34- PC (osteoclast
coculture)
[27]
CD19-CD45low/-CD38high/CD138+ PCs [30]
Int
erm
ed
iat
e P
C p
rec
urs
ors CD138+CD44+ give rise to short-lived PC
CD138+CD44-/CD138-CD44+ give rise to long-lived
PC in murine model candidates for the normal
counterpart of transformed MM cells
[44-46]
Table 1. Candidates for putative neoplastic PC precursors/MSC.
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2.1. Clonotypic B cells
Myeloma precursors that share identical variable diversity joining (VDJ) regions, rearrange‐
ments of immunoglobulin heavy chain gene (IgH) with patient’s tumor PCs and show a pre-
plasma cell phenotype are referred to as clonotypic B cells (CBL). They have been identified
in peripheral blood, lymph nodes and bone marrow [32, 36, 37, 47-49]. An extensive accumu‐
lation of somatic mutations in IgH gene and an absence of intraclonal variation suggest that
CBLs originate from post-germinal center B cells [37, 50]. Although the concept of clonotypic
B lymphocytes as neoplastic PC precursors is widely accepted, other studies suggest the
existence of MM precursors in other compartments (see Table 1). Additionally, phenotypic
profile and amount of CBLs vary among studies – e.g., it is not clear if these cells resemble
CD19+CD27+CD38- memory B-cells or carry a marker of hematopoietic stem cells, CD34 with
or without expression of the CD19 surface marker [21, 23, 35]. Furthermore, McSweeney et
al. (1996) did not find bone marrow CD19+ cells to be clonally restricted to kappa/lambda or
revealed any deviations of expression patterns of B-cell maturation markers from normal B-
cell components [51]. His results do not support a hypothesis of disturbed B-cell maturation
and development of the disease from early stages of B-cell ontogeny. Moreover, DNA analysis
proved that CD38++CD19- cells were aneuploid in most cases with a typical cell cycle profile
indicating the presence of a proliferating population, while cells expressing CD19 were
diploid. This suggests the existence of self-replicating plasma cell compartments that have a
capacity to replenish the tumor without the involvement of early B lymphocyte progenitors.
A number of studies that confirmed the presence of clonotypic B cells have been based mainly
on the detection of the same IgH rearrangements by PCR-based methods. The percentage of
MM patients with IgH-positive clonotypic B-cells ranged from 40% and 87% [36, 48, 52].
Limited dilution PCR assays detected the abundance of CBLs in 0.24% - 25% of peripheral
blood mononuclear cells (PBMC) and 66% of all peripheral B cells [32, 36, 52, 53]. This wide
range of occurrence may result from methodological errors of the PCR technique or expression
of atypical, non-clinical Ig transcripts [53]. The major disadvantage of the PCR method is that
this approach does not allow the morphological identification of cells of interest or sort cells
for subsequent functional analyses. In addition, it is important to take into account that the
presence of the same IgH rearrangements is reliable marker of clonality; it does not confirm
the malignity of cells per se. Therefore, the detection of IgH rearrangements in CD19+ cells could
also indicate that a small clone of premalignant or premyelomatous B cells persists despite the
transformation of other cells into malignant clones but this population does not actively
contribute to myeloma clones [51]. Rasmussen et al. (2010) suggests that peripheral blood
memory B cells represent pre-malignant, partially transformed remnants that could have some
proliferative advantage over normal memory B cells. They questioned the involvement of
CBLs in MM maintenance due to the fact these cells expressed specific ’early’ oncogenes
(FGFR3, MMSET, CCND1) that were deregulated by an IgH translocation but lacked ’late’
oncogene (KRAS) mutations [54].
A large interpatient and interstudy variability led Trepel et al., (2012) to establish patient-
individual ligands mimicking the epitope recognized by the myeloma immunoglobulin to
specifically target clonotypic surface IgH-positive B cells of MM patients [53]. In a cohort of 15
Multiple Myeloma - A Quick Reflection on the Fast Progress64
MM patients, semi-nested PCR using HCDR3-specific patient-individual primers detected
CBLs in 50% of peripheral blood and/or bone marrow samples. This frequency is line with
published data. However, a new flow cytometric protocol detected clonotypic B cells only in
one patient with a sensitivity of 10-3, ie. less than one clonotypic B cell per 1000 PBMCs. These
cells accounted for about 0.15% of PBMCs and 5% of B cells in this patient. Surprising dis‐
crepancies between these two approaches could indicate nonspecific annealing of the CDR3-
primer leading to false positive PCR results. Conclusions of this study suggest that the
abundance of CBLs is exceedingly low and has been enormously overestimated in previous
studies. Similarly to findings of Rasmussen et al. (2010), authors consider that unlike those
CBLs they are true “feeder” cells for malignant PC compartments and an essential prerequisite
of myeloma maintenance and progression [54]. In regard to the rare occurrence of CBLs in
MM, it is more likely that these cells are non-malignant remnants, which may be a part of the
malignant plasma cell clone but do not participate in tumor maintenance [53].
2.2. Clonotypic pre-switch B cells
An identical rearrangement of the IgH VDJ region with a consistent pattern of hypermutations
within the clone is a signature of CBLs. MM plasma cell clones generally express monoclonal
Igs of these isotypes: IgG, IgA, IgD, IgM, in rare cases kappa or lambda light chains and non-
secretory myeloma is detected [55]. Clonotypic isotypes with identical Vh gene sequences and
patterns of hypermutations linked to different classes of Ig heavy-chain constant region genes
(including Cμ gene) compared to clinical isotypes have been identified in some MM patients
[36-38, 56]. B cells with “non-clinical” isotype have been called pre-switch (IgM+) clonotypic B
cells. Particular classes of Ig are generated by mechanism of class switch recombination (CSR)
resulting in the formation of a hybrid switch region composed of switch region Sμ and a
respective isotype switch region (Cδ, Cγ3, Cγ1, Cα1, Cγ2, Cγ4, Cε and Cα2). Consequently,
immunoglobulin production is ‘switched’ from IgM to IgG and IgA (occasionally to IgD or
IgE). Sequences between the switch regions are cut out as a deletion loop after double-stranded
breaks without changing the VDJ sequence [57-59]. The presence of CSR is a hallmark of “post-
switch” B cells. However, pre-switch B cells do not seem to undergo CSR because IgH
transcript is composed of the clonotypic VDJ sequence still joined to Cμ gene [56].
Preswitch (IgM+) CBLs have been identified in BM and PB of most MM patients; however their
frequency is very low. Palumbo et al. (1992) have already suggested that MM may originate
from pre-switch cells [60]. Billadeau et al. (1993), using the allele-specific oligonucleotide PCR,
demonstrated the existence of the pre-switch isotype species that were clonally related to the
myeloma tumor. Another study also proved the evidence of pre-switch cells with somatically
hypermutated clonotypic VDJ region [37]. These cells exhibited expression of CD19 and HLA
class II or surface bound IgM. Reiman et al. (2001) described the presence of clinical and
nonclinical clonotypic isotypes in PB, BM and G-CSF – mobilized blood autografts of MM
patients. Expression of preswitch clonotypic transcripts persisted in the blood despite high-
dose chemotherapy with stem cell support suggesting drug resistance of this pre-switch
population. The persistence of preswitch clonotypic isotypes was associated with reduced
survival and with a more advanced disease at the time of diagnosis. Moreover, both pre‐
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switched and postswitched cells were able to engraft in the NOD/SCID mice indicating their
potential clinical relevance. Authors considered the fact that MM is the disease of post-switch
cells, IgH isotype switching in MM may accompany worsening disease [38]. Despite these
facts, Taylor et al. (2008) questioned the role of preswitch (IgM+) clonotypic cells as a progenitor
pool for postswitch MM-PCs. They hypothesized that if they are progenitors for MM-PCs,
multiple clonotypic switch junctions, or changes in the switch junction, are expected in the
postswitch progeny. However, results of specific clonotypic-switch PCR determined the
presence of a single, unchanged clonotypic switch junction. Thus, postswitch MM-PCs most
likely originate from a single CSR event and pre-switch IgM+ cells do not represent MM-PC
progenitors [52].
Interestingly, pre-switch (non-clonotypic) IgM+ CD27+ cells with mutated IgH V region have
been detected in various immunodeficiencies and autoimmune diseases but also in healthy
donors [61, 62]. Expression of surface marker CD27 suggests that these cells maybe IgM+ CD27+
memory B cells. On the other hand, considering the occurrence of IgM+ CD27+ cells in humans
who cannot form germinal centers (GC), it was presumed that these cells: 1) are generated
independently of germinal centers and therefore cannot represent a subset of memory B cells;
2) undergo SHM during generation of the preimmune repertoire; and 3) they mediate
responses to T cell-independent antigen. The evidence for these presumptions came from the
studies of patients with hyper-IgM syndrome, X-linked lymphoproliferative disease or
common variable immunodeficiency that are characterized by some type of defect in GC
formation. However, quantification of IgM+ CD27+ cells in these diseases showed that their
numbers reached approximately 20–40% of the number observed in normal individuals. These
results indicate that germinal centers may play a role in the development of IgM+ CD27+ cells.
IgM+ memory B cells may be generated at the centroblast stage and undergo SHM but leave
GC before the onset of isotype switching. Whether IgM+ CD27+ cells with mutated IgH V region
might be a source of preswitch (IgM+) CBLs, it remains a matter of further debate and research.
2.3. Clonogenic CD138- cells
Matsui et al., (2004) suggested that the source of MSC responsible for the initiation and
maintenance of MM might be due to a minor population of less differentiated cells reminiscent
of memory B-lymphocytes with surface markers CD20+CD27+CD34-CD138-. They showed that
CD138-/CD34- cells derived from MM cell lines RPMI 8226, NCI-H929 and primary clinical
samples were clonogenic in vitro. Cloning efficiency correlated with the disease stage [6]. The
depletion of either CD20+ or CD27+ cells from the CD138-/CD34- population significantly
limited clonogenic growth of MM, therefore the phenotype of MM cells with in vitro clonogenic
potential were suggested to be characterized by a pattern of surface markers
CD20+CD27+CD138- [39]. Clonogenic potential of CD138-/CD34- cells was evaluated by
successful engraftment of non-obese diabetic/severe combined immunodeficiency (NOD/
SCID) mice during both primary and secondary transplantation. CD138+/CD34- were unable
to form colonies in vitro and human engraftment was not detected in any of the mice injected
with CD138+ cells. A chimeric anti-CD20 monoclonal antibody, rituximab, was showed to
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inhibit clonogenic growth of CD138- cells in vitro [6,39]. However, clinical trials failed to
confirm an effect of rituximab as a useful maintenance therapy for MM [63, 64].
Paino et al., (2011) reevaluated the presence and function of CD20+ putative MSC in a panel of
myeloma cell lines [65]. Although, Matsui et al. (2004) described a small population (2-5%) of
CD138-20+ cells in NCI-H929 and RPMI-8226 cell lines, Paino et al. (2011) were not able to detect
CD20 by flow cytometry in the majority of tested MM cell lines [6, 65]. Only RPMI-8226 cell
lines contained a small population of CD20dim+ cells (0.3%). These data are consistent with the
report of Rossie et al. (2010) that showed that U266, NCI-H929 and RPMI-8226 MM cell lines
are CD20- [66]. Despite previous results, memory B-cell phenotype of putative CD20+ MSC was
also not confirmed. On the contrary, CD20dim+ cells displayed a myelomatous plasma cell
phenotype: CD38+CD138+CD19-CD27-CD45-. Additionally, CD20dim+ cells did not exhibit stem
cell properties and compared to the CD20- population they showed a lower level of self-
renewal potential. Both populations developed plasmacytomas when they were injected into
CD17-SCID mice suggesting that CD20dim+ cells are not essential for tumor formation. Fur‐
thermore, sorted and plated CD20dim+ cells did not differentiate into CD20- cells. However,
CD20- cells give rise to CD20dim+ cells indicating a hierarchical order of differentiation from
CD20- to CD20dim+ cells. Overall, these results do not support CD20 as a marker associated with
MSC phenotype [65].
Other drugs, such as dexamethasone, lenalidomide, bortezomib, or 4-hydroxycyclophospha‐
mide did not significantly affect CD138- cells indicating resistance to some conventional or
novel therapy, a characteristic feature of CSC [39]. All four agents significantly inhibited the
clonogenic growth of CD138+ cells isolated from MM cells. Nevertheless, it could not be
evaluated in CD138+ PCs from MM patients because they lack in vitro clonogenic activity.
Detection of a small CD138- population of MM cell lines (< 2%) that displayed stem cell
properties mediating drug resistance, such as the capacity to efflux the DNA binding dye
Hoechst 33342 and higher relative levels of aldehyde dehydrogenase (ALDH) activity further
supports the existence of a resistant MSC compartment in MM. Moreover, CD138- cells of MM
cell lines also exhibited cellular quiescence similar to adult stem cells – almost all CD138- cells
were shown to remain in G0 – G1 phase and less than 1,5 % in S phase, compared to two thirds
of CD138+ cells in G0 – G1 and about 20% in S phase [39]. On the other hand, results of the first
study proved that CD138- cells isolated from the same MM cell lines expressed higher levels
of the proliferation marker Ki67 than CD138+ cells [6]. These discrepancies might come from
different passages of cell lines or culture conditions but cannot conclusively prove a quiescent
state of CD138- cells.
Besides the clonogenic population of CD138- cells, Matsui et al. (2004) also isolated circulating
clonotypic CD19+CD27+ B cells in peripheral blood of MM patients which were successfully
engrafted into NOD/SCID mice. However, it remains unclear whether CD138- clonogenic cells
are identical to clonotypic CD19+ B cells. Hosen et al. (2012) examined 16 MM samples and
found that only CD138-CD19-CD38++ cells formed colonies in vitro whereas CD19+ B cells did
not [67]. Moreover, CD138-CD19-CD38++ cells engrafted into SCID-rab mouse models in 3 cases
out of 9, whilst there was no detection of CD19+ B cell engrafment. Neither CD19+ B cells
transplanted into NOD/SCID IL2Rγc(-/-) mice propagated into MM. Surprisingly, CD138+ PCs
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also give rise of MM, but more slowly than CD138- cells. Thus, CD138-negative clonogenic
cells might represent a population which has the potential to give rise to MM but does not
overlap with the population of CD19+ B cells. These results indicate that CD138-negative
clonogenic cells are more PCs than B cells but this does not necessarily mean that Matsui’s
myeloma stem cell concept is wrong. Although, MSCs phenotypically resemble memory B
cells, they may be modified PCs and CD138-positive PCs might represent some “transit”
population that subsequently lost its mature phenotype (this will be discussed later). However,
Christensen et al. (2012) reexamined CD138- population of so called MSC and obtained
surprising results which were strongly controversial to both previous mentioned reports [68].
An analysis of primary CD138+ PCs of MM patients showed that the number of CD138- cells
increased in parallel with increasing time from sampling to analysis. In regards to the fact that
myeloma PCs loses expression of the surface antigen CD138 in apoptosis, Annexin V was
included in all analyses to monitor apoptotic cells [69]. Expectedly, if a CD138- population was
detected, these cells were positive for Annexin V. Similar results were also obtained by Chiron
et al. (2011). Furthermore, qPCR techniques confirmed similarly high levels of CD138 mRNA
in both CD138- and CD138+ MM cells. CD138- and CD138+ subpopulations varied neither in
expression of CD19 nor in expression of CD20. These contradictory results would imply that
the CD138-negative population may represent only cells undergoing apoptosis as a conse‐
quence of previous sample handling [68]. Nevertheless, these new findings cannot completely
deny results of previous studies that showed the potential of CD138- cells to form colonies in
vitro and engraft mouse models.
2.4. Side population
Side population (SP) cells were defined based on their capacity to exclude dyes such as Hoechst
33342 [70]. Hoechst 33342 dye binds to the AT-rich regions found in the minor groove of DNA.
Upon UV excitation, cells with this efflux capacity can be identified as the minor population
of the positively stained cells sideways from the diagonal in FACS analysis plots. SP cells have
been detected in various cancer cell lines as well as primary tumors (rev. in 71). Side population
possesses CSC characteristics such as the capacity for regrowth of the tumor, expression of
stem cell-like genes and resistance to chemotherapy. This is why SP cells are believed to be the
true population responsible for tumor maintenance.
The presence of SP cells were investigated in four MM cell lines, RPMI 8226, U266, OPM2 and
KMS-11, and primary MM samples [42]. SP was defined using control cells stained with both
Hoechst and verapamil, L-type calcium channel blocker, to establish the SP gate[72]. Reduction
of SP cells was demonstrated in all tested cell lines. In 18 of 21 bone marrow samples from MM
patients the percentage of SP cells ranged from 0 to 4.9% compared to 0.05% of SP in normal
bone marrow. There was neither a significant difference between treated and non-treated MM
patients based on the percentage of SP nor a correlation between the percentage of SP and the
paraprotein concentration or disease stage. 0.18–0.83% of SP cells express the clonal surface
immunoglobulin light chain restriction that matched 89–97% of each patient’s PCs. SP cells
were also analyzed for the expression of CD138. A mean of 96.1% of SP cells were found to be
CD138-. However the CD138+ fraction also contained SP indicating that they are present in
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both CD138- and CD138+ compartments. Jakubikova et al. (2011) also demonstrated that the SP
fraction of MM cell lines expressed CD138 antigen [43]. Moreover, these results did not prove
a correlation between expression of CD19, CD20, or CD27 and the proportion of SP cells.
Conversely, SP cells showed more clonogenic potential and proliferation index than the main
population. Furthermore, adherence to stromal cells increased percentage, viability and
proliferation potential of SP cells. Supportive role of BM microenvironment was attenuated
by lenalidomide and thalidome. Lenalidomide itself directly decreased the percentage and
clonogenicity of SP cells. This study demonstrated innovative and promising strategies for
targeting putative myeloma-initiating cells and prevention of relapse.
Although SPs exhibit stem cell properties and might represent a “feeder” population respon‐
sible for the relapse of the disease, others question the method for detection of SP. Hoechst
staining binds to DNA resulting in toxicity to live cells, that is why SP cells might represent
only a population that survived the lethal effect of Hoechst. SP phenotype might also be
affected by staining time, dye concentration or cellular concentration. The problem also lies in
cytometric approaches that showed inconsistencies among gating strategies and might lead to
contamination of the SP fraction by non-SP cells. Furthermore, usage of verapamil as an
inhibitor of efflux was also criticized because verapamil-sensitive cells were detected in the
negative or SP gate [73]. These problematic findings require more stringent gating strategies
to clear doubts about SP.
2.5. Clonogenic plasma cells
The clonogenic potential of primary MM cells was first demonstrated by Hamburger & Salmon
(1977). They showed that freshly explanted human myeloma cells are able to form colonies of
monoclonal PCs. Colonies consisted of immature plasmablasts and mature PCs. Drewinko et
al., (1981) investigated the growth fraction of MM cells. In untreated and nonresponsive
patients the growth fraction represented 4% of MM cells. Patients in relapse had the growth
fraction ranging from 14% to 83%. Nonproliferating fraction contained true quiescent cells,
some proliferating cells with very long intermitotic times, and some proliferating cell that have
entered the maturation phase. Although these two reports demonstrated clonogenic and
proliferative capacity of primary MM tumors, these cells were not phenotypically defined as
whole mononuclear fraction of BM was used for analyses. Therefore, results of these studies
cannot answer what kind of cells represents true growth fraction.
First experiments demonstrating the clonogenic growth of phenotypically defined PCs were
carried out by Yaccoby and Epstein (1999). They proved that CD38++CD45- PCs derived from
PB and BM are able to engraft severe combined immunodeficiency (SCID)-hu host system with
implanted human bone. Circulating clonal PCs grew more rapidly in SCID-hu hosts than those
in the BM suggesting that this may represent a subpopulation with a higher growth potential.
In contrast to previous reports, PC-depleted blood cells did not give rise to MM in SCID-hu
hosts [7]. Yata & Yaccoby, 2004 presented an alternative model for study of myeloma-initiating
cells (MIC) that uses rabbit bones implanted subcutaneously in unconditioned SCID mice. The
SCID-rab model was also successfully engrafted with CD138+ PCs of MM patients. Although,
these two models did not show a serial engraftment of the disease, they strongly indicate a
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critical role of specific bone marrow microenvironments for plasma cell survival and prolif‐
eration [28].
A dependence of myeloma PCs on human BM microenvironment was clearly demonstrated
in an experiment with NOD/SCID/common cytokine receptor γ chain-deficient (NSG) and
recombinase-activating gene 2/common cytokine receptor γ chain-deficient (RAG2-/ γ c-) mice
[30]. Results proved that CD138+/CD38high cells from MM patients led to a repopulation of
CD19+CD38low or CD138+CD38+ B-lineage cells in human bone-bearing mice but no engraft‐
ments were detected in human bone-free mice even after orthotropic intrafemoral injection.
Moreover, serially xenotransplantated CD19-CD138+ cells preferably engrafted from a human
bone graft but were not detected in any mouse hematopoietic tissues. All grafts derived from
CD138+/CD38high cells were clonally related to myeloma PCs, whereas engraftments of
CD19+CD38low/- B cells were polyclonal CD19+CD38low cells. Further fractionation of CD138+/
CD38high cells and theirs subsequent xenotransplantation showed that CD45low/- or CD19-
CD38high/CD138+ cells had a higher engraftment ability than CD45high or CD19+ plasmablasts.
In line with the above mentioned results, it was concluded that CD19-CD45low/-CD38high/
CD138+ PCs rather than CD19+ B cells or plasmablasts enrich for MICs. In addition, analysis of
clonogenic potentials of CD138+ and CD138- populations derived from plasma cell leukemia
patients strongly favored these findings [29]. This study demonstrated that, though, CD138+
PCs derived from plasma cell leukemia patients formed colony forming units (CFU) in a very
low frequency, no CFU were found when CD138- cells were seeded. Harvested cells of CFUs
derived from CD138+ PCs were strongly positive for CD138 but negative for CD20. There was
no evidence that they can be CD138-CD19+CD20- plasmablasts or CD19+CD20+CD138- B-cells.
These findings further underline an important role of CD20-CD138+ population as a conceiv‐
able reservoir of clonal PCs at least in plasma cell leukemia.
Against the statement that CD138-positive PCs represent a “feeder” population responsible
for incurability of MM is the fact that abnormal PCs show a low proliferation potential with a
plasma cell labeling index (PCLI) ranging from 0.5% in MGUS to 1% in early MM, PCLI.
Therefore, the growth fraction of progenitor cells giving rise to MM has been expected in less
differentiated stages of B cell development. Despite low proliferative activity of malignant PCs,
PCLI is one of the most important prognostic factor with a strong impact on overall survival
[98, 99]. Additionally, limited proliferation potential of PCs could be explained by error
reduction during DNA synthesis that was proposed for normal adult stem cells that are highly
clonogenic but proliferatively silenced [100].
2.6. Intermediate plasma cell precursors
O’Connor et al. (2002) identified post-GC-precursors in a mouse model that might contribute
to long-lived humoral immunity. These cells were distinct from splenic B cells, mature or
memory B cells as well as mature PCs. Mediate levels of CD138 indicated that PC precursors
might represent a transition state of PC development. PC precursors were demonstrated to
migrate to the BM where they proliferate and persist for a long period of time and consequently
differentiate to mature PCs without antigen stimulation. CD138+CD44+ give rise to short-lived
PCs, CD138+CD44- or CD138-CD44+ differentiated to long-lived PCs. Two roles of PC precur‐
Multiple Myeloma - A Quick Reflection on the Fast Progress70
sors were suggested; (i) they might either serve as a reservoir of PCs upon PC attrition or (ii)
contribute to post-GC affinity maturation of the humoral immune response. Due to similarities
of phenotype, proliferative potential, and differential capacity of the PC precursors to putative
MM progenitors, authors suggested that these cells are candidates for the normal counterpart
of transformed MM progenitors [74].
The true origin of MM remains a matter for further debate. An unanswered question persists
whether clonotypic CD138- cells or side populations represents myeloma precursors or
phenotypic variants of the MM tumor cells that have lost some plasma cell markers and gained
some B-cell markers as Yaccoby (2005) suggested [27, 54]. He presented a new model for
myelomagenesis; that mature CD45low/intermediate CD38high CD138high, CD19−CD34− PC situated
closely with osteoclasts in the lytic bone lesions reverse senescence, acquire a stem cell
phenotype, (CD45intermediate/high CD19low andCD34low), and become quiescent and apoptosis-
resistant. This indicates that myeloma PCs have plasticity that allows them to reprogram,
dedifferentiate and acquire autonomous survival properties which are responsible for drug-
resistance and relapse of MM patients. Similar results were also obtained by Kukreja et al.
(2006) when cultured U266 myleoma cell line and primary myeloma PCs with dendritic cells
(DC). The coculture of U266 cells and DCs led to an increase in the proportion of cells lacking
CD138; a marker of terminally differentiated PCs, and induction of B cell lymphoma 6 (BCL6)
expression. It was suggested that BCL6 plays an important role in survival and self-renewal
of germinal center B cells and that suppression of BCL6 is a critical feature of normal PC
differentiation. Furthermore, a presence of DCs in the culture enhanced clonogenic growth of
the myeloma cell line and as well as primary myeloma PCs [75]. Just as in the previous report,
this data suggests that the differentiation state of myeloma cells is plastic and can be modified
in the presence of DCs. Both reports emphasize an importance of tumor microenvironments
for myleoma plasticity. Whether myeloma PCs exhibit plasticity that might be responsible for
phenotypic heterogeneity of MMs, and also form inconsistencies among myeloma stem cell
concepts, it will be discussed further.
3. Phenotypic heterogeneity of multiple myeloma
The high phenotypic heterogeneity of clonal PCs is a hallmark of MM; abnormal PCs fre‐
quently express a wide spectrum of multi-lineage antigens such as myeloid, T-cell and natural
killer-associated antigens. Compared to normal polyclonal PCs which show high CD38 and
CD138 expression along with the B-lymphocyte marker CD19 abnormal PCs generally lack
CD19 expression, show variable expression of CD45, dim expression of CD38 and heteroge‐
neous signals of CD138. Further, they have weaker expression of CD27, increased expression
of CD28, CD33 and CD56 and variable expression of CD20 and CD117 (rev. in [76, 77]). Causes
of phenotypic heterogeneity remain unclear.
PCs belong to the B-cell lineage that expresses paired box protein 5 (PAX5) and its target, CD19.
PAX5 activation and inactivation is essential for early B cell commitment as well as for
maintenance of the functional identity of B cells throughout B cell development. PAX5
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represses B lineage 'inappropriate' genes and simultaneously activates B lineage-specific genes
[78, 79]. Conditional PAX5 reduction in late B lymphocytes promotes development to the
mature B cell stage. PAX5 and CD19 expression are considered to be downregulated or lost
but it has been reported that expression of PAX5 and CD19 is restored in normal PCs of pleural
effusion, ascitic fluid and BM aspirate. In contrast to normal PCs, clonal PCs of MM do not
express PAX5 or CD19 (> 95% of cases) [80, 81].
Phenotypic heterogeneity of abnormal PCs might reflect a certain degree of dedifferentiation
of these cells. It has been previously shown that elimination of PAX5 shifts B cells to multi-
potency [82]. Therefore expression of multi lineage markers on clonal PCs might be due to a
lack of PAX5 gene expression but not only as a consequence of malignant transformation. Cell
heterogeneity is the phenomenon that is commonly seen in many cancer types. The cause of
this variability might be due to the loss of the lineage master gene which can lead to dediffer‐
entiation or transdifferentiation into cells of other lineages [83].
The ability to differentiate into multiple lineages is a characteristic feature of pluripotent
embryonic stem cells. However, pluripotency does not necessarily have to be limited to a
population of undifferentiated stem cells of the early embryo and lost irreversibly upon
terminal differentiation [84]. Fully differentiated somatic cells can be reprogrammed into
inducible pluripotent stem cells (iPSC) by ’forced’ expression of pluripotency/reprogramming
factors: OCT4, SOX2, c-Myc and KLF4 or NANOG, LIN28, c-Myc and KLF4 [85, 86]. Human
somatic cells from all three germ layers, including human differentiated mature B lympho‐
cytes, have been successfully reprogrammed [87-93] Reprogramming of mature B cells
required additional ‘sensitization’ by the myeloid transcription factor CCAAT/enhancer-
binding protein-α (C/EBPα) that causes a disruption of PAX5 functions, or a specific knock‐
down of the B cell transcription factor PAX5. This indicates that the loss of PAX5 expression
might be associated with gain of stem cell features for mature PCs and represent one of the
key events in the pathogenesis of MM.
4. Plasticity of multiple myeloma
There is growing evidence that MM encompasses a certain degree of plasticity that might be
responsible for expression of a wide spectrum of multi lineage markers and discrepancies
among myeloma stem cell theories. Two facts support this hypothesis:
i. There is a strong link between induction of pluripotency and tumor progression;
several human cancers acquire stem cell-like plasticity upon (re)expression of
reprogramming factors. It raises the possibility that dedifferentiation is a key
mechanism for the generation of tumor-initiating cells in human cancer [84]. The
process of dedifferentiation is suggested to be under control of tumor microenviron‐
ment. Interaction of tumor cells with their microenvironment might induce altered
differentiation; epithelial-mesenchymal transition (EMT) which has been observed
in some solid tumors [94, 95]. Similarly to MM, phenotypic plasticity of myeloma PCs
were observed in long-term co-culture with osteoclasts; myeloma PCs lost their
Multiple Myeloma - A Quick Reflection on the Fast Progress72
mature phenotype and dedifferentiated to an immature, resilient, apoptosis-resistant
phenotype. In addition, CD138+ PCs cocultured with DCs lost expression of CD138
and increased the clonogenic potential [75]. It raises the possibility that signals from
the microenvironment can (reversibly) alter the phenotype of PCs and cause obvious
heterogeneity of MM. This regulation might keep dynamic equilibrium between CSC
and non-CSC compartments [96].
Dynamic state between CSC and non-CSC like compartments were also observed in a
subpopulation of differentiated basal-like human mammary epithelial cells that spontaneous‐
ly converted to stem-like cells in vitro and in vivo. Moreover, oncogenic transformation
enhances this spontaneous conversion. These findings indicate that normal and CSC-like cells
can arise de novo and indicate the importance of the differentiation state of cells-of-origin as a
critical factor determining the phenotype of their transformed derivatives [97]. Whether
mature PCs exhibit a plasticity potential responsible for dedifferentiation into cells with stem
cell like properties is questionable but highly attractive. Confirmation that mature PCs have
the capacity to convert into CSCs could resolve current inconsistencies among myeloma stem
cell theories and help to target the population responsible for relapse of the disease.
ii. Despite of mature phenotype, myeloma PCs have been reported to express pluripo‐
tency factors (SOX2, c-Myc or KLF4) and stem/progenitor markers, such as germline
stem cell markers of the MAGE family, the hematopoietic progenitor marker CD117
or neural stem cell marker nestin [83, 101-105]. Some of these factors provide valuable
prognostic information. Currently, the role of c-myc is growing as the key transform‐
ing factor in the progression of asymptomatic MGUS to a symptomatic disease [101].
SOX2 and MAGE have been demonstrated to be relevant targets for immunotherapy
due to their immunogenicity. Interestingly, MGUS patients frequently mount a
humoral and cellular immune response against SOX2 but MM patients lack anti-
SOX2 immunity [104, 106]. CD117 (c-kit) is an essential hematopoietic growth factor
receptor with tyrosine-kinase activity. Aberrant expression of CD117 is detected on
a subset of MGUS and MM and is associated with a favorable outcome for MM
patients [107, 108]. KLF4 was described in regulation of apoptosis, proliferation and
differentiation of B cells and B-cell malignancies. Strong up-regulation of KLF4 was
detected in MM cell lines in the process of apoptosis suggesting a role of KLF4 in MM
progression [105]. Nestin is a remarkable protein that is found in rapidly dividing
cells of developing and regenerating tissues [109]. Therefore, it is surprising that this
gene and protein expression of the stem cell marker nestin has been detected in
terminally differentiated PCs of MM patients [83, 110]. Moreover, our recent work
proved that nestin protein is a tumor specific marker for CD138+38+PC of MM [110].
Expression of nestin, a marker of stem/progenitor cells in malignant PCs that are
considered to be terminally differentiated, is highly controversial and indicates that
nestin might play an exceptional role in the pathology of MM. However, biological
or clinical implications of nestin have not been determined in monoclonal gammo‐
pathies or other hematological malignancies so far.
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Summarizing these findings supports the hypothesis that stem cell-like features are not rare
in monoclonal gammopathies and might indicate the existence of inducible stem cell properties
in more differentiated cells than was initially thought [27, 111] (see Fig. 2).
Figure 2. Model of inducible stem cell properties in myeloma
5. Putative role of nestin in myeloma plasticity
Neural stem cell marker nestin was first identified in neuroepithelial stem/progenitor cells of
the rat central nervous system (CNS) by Hockfield and McKay in 1985 [112]. Nestin is detected
in a wide range of undifferentiated tissues under normal and pathological conditions
[113-116]. Expression of nestin is a common feature of multipotent proliferative progenitor
cells with self-renewal and regeneration potentials. During terminal differentiation, nestin
expression is silenced but can be reactivated upon injury or other pathological conditions such
neoplastic transformation. The human nestin gene is located at 1q23 locus and is composed of
four exons and three introns. Nestin expression is driven by a minimal promoter that is
activated by transcriptional factor Sp1 [117]. Moreover, epigenetic regulation was also
demonstrated. Results indicated that histone acetylation might be sufficient to mediate
activation of nestin transcription [118].
Nestin protein belongs to a large family of intermediate filament (IF) proteins that are encoded
by more than 70 genes expressed in a time and site-specific manner in metazoan cells. Members
of the IF family are divided into six classes of proteins according to their structure, properties
and localization [119]. Nestin, a class VI protein, is characterized by a α-helical central ’rod’
domain which is typical for all IF, that contains repeated hydrophobic heptad motifs, a short
N-terminus (head) and a very long C-terminus (tail) (Fig. 3) C-terminus is suggested to
function as a linker or cross-bridge between intermediate filaments, microfilaments and
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microtubules [120]. The molecular weight of human nestin protein is ~ 200 – 220 kDa; more
often it is found in its glycosylated form with molecular weight of 240kDa [121, 122]. Nestin
does not fold by itself most likely because of its very short N-terminus. Therefore, nestin
requires the presence of other IF proteins such as type III vimentin, desmin or type IV α-
internexin [109, 123, 124].
Figure 3. Structure of intermediate filaments (adopted and modified from Michalzyk & Ziman, [2005]
5.1. Cellular roles of nestin
An important regulator of nestin organization and dynamics during mitosis is cdc2-mediated
phosphorylation. Phosphorylation/dephosphorylation of nestin may modulate disassembly
and assembly of intermediate filaments [125]. These processes might play a role during
increased cytoplasmic trafficking in progenitor cells undergoing division or in migrating
interphase cells [126-128]. Nestin was shown to participate in asymmetric redistribution of
cytoskeletal proteins and other factors to daughter neuroepithelial cells [129]. Nestin structure
serves also as a scaffold for cdk5/p35 activity resulting in a cytoprotective effect against stress
induced cell death in neural progenitor cells [122, 130]. Moreover, nestin is supposed to be a
major determinant in suppression of anti-proliferative activity of glucocorticoid receptors (GR)
in undifferentiated tissues by anchoring GRs in cytoplasm but cells lacking nestin accumulate
GRs in the nucleus [131]. This mechanism might be responsible for glucocorticoid resistance
seen in many cancers.
5.2. Nestin in multiple myeloma
Biological or clinical implications of nestin have not been systematically studied in monoclonal
gammopathies or other hematological malignancies so far. The first mention of nestin expres‐
sion in MM was described in malignant PCs of 5 MM patients and two myeloma cell lines
(NOP2 and Liu01) by Liu et al. (2007). Authors referred to the existence of CD56+ primary MM
cells expressing neuronal markers, such as nestin, neuron-specific enolase and β-tubulin III
[83]. Expression of nestin was reported to be stimulated by the Notch signaling pathway in
human gliomas [132]. The Notch pathway plays also an important role in survival and
proliferation of malignant PCs and negatively affects bone disease in MM [133]. Our recent
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work proved that nestin protein is a tumor-specific marker for CD138+38+PC of MM patients
[110]. Regarding the fact that myeloma PCs appear to be mature, terminally differentiated cells
with a low proliferative potential, the presence of nestin is very surprising. Cells expressing
nestin may represent a transient population undergoing dedifferentiation into CSC-like
phenotype. Providing that PCs possess a truly dedifferentiation potential, the direction of
dedifferentiate needs to be elucidated and whether or not this process is reversible.
Unexpectedly, our results showed that nestin was present in one-third of cases in 50% to almost
100% of PCs. Also expression of MAGE genes was found in majority of PCs [102, 134]. Thus,
if nestin is expressed in most cells, it means that majority of PCs might gain stem cell features
and could repopulate the tumor after therapy. These findings take into question the hierarch‐
ical model of myelomagenesis based on the presumption that MM originates from a minor
population of MSC. Conversely, stochastic clonal evolution model better describes mecha‐
nisms responsible for recurrence of MM. This model suggests that majority of tumor cells have
a character of stem cells and may repopulate tumor cells after treatment [135]. Plasticity of PCs
better fits the clonal evolution model because weakly proliferating PCs would not be able to
quickly repopulate the tumor, therefore we hypothesized that they need to convert into more
rapidly dividing cells.
Association of nestin with plasticity of terminally differentiated cell types were demonstrated
in the study of metaplastic conversion of mature pancreatic epithelial cells [136] Metaplastic
conversion is defined as the replacement of one differentiated cell type by another mature cell
type and is frequently associated with an increased risk of subsequent neoplasia. Causes of
these changes remains unclear but one possible mechanism may be transdifferantiation of one
mature cell type to another one either directly or via an undifferentiated transient cells (rev.
in [137]). Means et al. (2005) showed that mature acinar cells can convert into ductal epithelia
under EGFR signaling. Metaplastic changes were accompanied by occurrence of nestin-
positive intermediates similar to nestin-positive precursors observed during early pancreatic
development. Results of this study proved a real trans-differentiation potential of mature
mammalian cells and indicated that plasticity of mature cell types may play a role in the
generation of neoplastic precursors. Whether nestin-positive myeloma PCs might represent
particular intermediates undergoing changes leading to the occurrence of cells with a changed
(transdifferantiation) or less differentiated phenotype (dedifferentiation), it remains a matter
for future research. On the other hand, nestin expression might represent only a byproduct of
tumor transformation without any association with myeloma heterogeneity. However, the
dynamic character of nestin network plays an important role in the key cell processes such as
proliferation, migration and cell survival. Nestin polymerization/ depolymerization influences
intracellular signaling, it is likely responsible for rapid redistribution of intracellular proteins,
cytoskeletal remodeling and/or might function as a scaffold for protein interactions [122, 125,
129, 130] (Fig. 4). All these properties might represent an important prerequisite for myeloma
plasticity.
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Figure 4. Nestin remodeling and cellular functions
6. Cancer stem cell phenotype and tumor microenvironment
Recent knowledge supports the hypothesis that altered BM microenvironments participate in
both mechanisms leading to tumor progression; induction of stem cell features and stimulation
of angiogenesis. Cancer stem cell phenotypes may be a plastic state induced in cancer cells
depending upon microenvironmental signals, such as hypoxia. Hypoxia has a great impact on
the production of angiogenic factors but it is also a crucial regulator of the stem cell phenotype.
Several reports have shown that hypoxia and HIFs are involved in maintaining a stem-like
state in normal tissues [138]. One example can represent hematopoietic stem cells that reside
in regions regulated by oxygen tension. It is hypothesized that undifferentiated phenotypes
of these cells relies on HIF activity in hypoxic areas. Hypoxic areas in tumors might be an
analog to stem cell niches in normal tissues. Furthermore, Yoshida et al. (2009) have shown
that hypoxic conditions significantly improve generation of iPSC [139]. Growing knowledge
of cancer stem cell biology suggests that hypoxia may act as a critical regulator of the cancer
stem cell phenotype.
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Series of experiments have demonstrated that hypoxia is responsible for altering the cellular
phenotype by causing an increase in proliferation, self-renewal and upregulation of stem cell
genes in both CSC and non-CSC. Several groups have shown that hypoxia can regulate histone
methylation and thus alter the epigenetic status of cancer cells [140-142]. Tumor hypoxia also
correlates with poor outcome of patients. HIFs were shown to induce the embryonal stem cell-
like transcriptional program, including OCT4, NANOG, SOX2, KLF4, MYC, and micro‐
RNA-302 in cancer cell lines of prostate, brain, kidney, cervix, lung, colon, liver and breast
tumors [143]. Hypoxic microenvironment potentiates biological effect of Notch signaling in
adenocarcinoma of the lung or alters gene expression of neuroblastoma cells to induce more
immature phenotype [144, 145]. CD133, a cancer stem cell marker, has been reported by several
groups to be upregulated under hypoxic conditions [146, 147]. McCord et al. [2009] showed
that hypoxia not only increased the sub-population of glioblastoma cells positive for CD133,
but also enhanced expression of other stem cell markers, such as SOX2, OCT4 and nestin [148].
Low oxygen levels induced also HIF-2α expression that can increase the expression of stem
cell-associated genes and confer tumorigenic potential to non-CSC [140].
The BM microenvironment of MM is also hypoxic, and myeloma PCs are long term exposed
to low oxygen levels. Tumor adaptation to hypoxia is mediated by the production of HIF-1
[149]. Both HIF-1α and HIF-2α have been reported to be activated in MM patients resulting in
stimulation of angiogenesis [150]. Although a role of BM microenvironment is generally
recognized as a crucial factor affecting myeloma development and support progression, it is
surprising that an importance of hypoxic microenvironment for modulation of plasma cell
phenotype have never been studied in MM.
7. Conclusion
Despite the achievements of currently used therapy, MM remains difficult to treat. Novel
agents such as inhibitors of proteasome or immunomodulatory drugs have prolonged survival
of patients with MM and even some patients persist in long term remission. However, there
is a little known about mechanisms of myeloma development or the population responsible
for the origin and relapse of the disease. Many scientists have tried to explain causes of the
relapse but none of their theories have been conclusively confirmed so far. In this review, we
explain inconsistencies among particular concepts and the inability to detect cells of origin by
the plasticity potential of myeloma PCs. Plasticity of myeloma PCs might be a cause of vast
phenotypic heterogeneity of MM and different characteristics of putative myeloma precursors.
Under specific signals from aberrant microenvironments, PCs might undergo dedifferentia‐
tion/transdifferentiation changing their phenotype profile, and acquire stem cell-like proper‐
ties to ensure survival. Therefore, an effort to target the specific cell type based only on surface
markers is not sufficient. Instead, it is necessary to concentrate on pathologic mechanisms
responsible for the transition from non-CSC to CSC like cells. Additional focus on adjacent
microenvironments and specific prevention of stem cell-like conversion might increase success
of future therapy.
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